

**What is important to you
about arthritis medicines?**

Things to Consider?

How Often?

Side Effects?

How Soon?

Cost?

How Long?

Avoid these medicines if you...

-  : have liver disease
-  : have TB (you may need to be tested)

While taking these medicines you should...

-  : **not** become pregnant
-  : **not** drink alcohol
-  : **not** receive *live* vaccines

Medications require blood test monitoring.

Pick another topic



Leflunomide
(Arava®)



Sulfasalazine
(Azulfidine®)



Methotrexate
(Rheumatrex® or Trexall®)



Etanercept
(Enbrel®)

Adalimumab
(Humira®)

Anakinra
(Kineret®)

Canakinumab
(Ilaris®)



Abatacept
(Orencia®)

Infliximab
(Remicade®)

Rituximab
(Rituxan®)

Tocilizumab
(Actemra®)



There is no way to predict which, if any, of these side effects you will experience.

Pick another topic



Leflunomide
(Arava®)

Sulfasalazine
(Azulfidine®)

Common:

- stomach upset
- diarrhea
- headache
- cold symptoms

Uncommon:

- low blood counts
- severe liver injury (Leflunomide only)
- severe skin reaction (Sulfasalazine only)



Methotrexate
(Rheumatrex® or Trexall®)

- mouth sores
- nausea
- stomach upset
- headache

- abnormal liver test
- low blood counts
- lung inflammation



Etanercept
(Enbrel®)

Anakinra
(Kineret®)

Adalimumab
(Humira®)

Canakinumab
(Ilaris®)

- redness or soreness where needle enters skin
- common cold
- sinus infection
- stomach upset
- headache
- itchy or allergic rash

- TB may come back
- serious infection that needs antibiotic
- low blood counts
- development of autoantibodies
- muscle inflammation
- cancers like lymphoma



Abatacept
(Orencia®)

Rituximab
(Rituxan®)

Infliximab
(Remicade®)

Tocilizumab
(Actemra®)

- common cold
- sinus or throat infection
- stomach upset
- headache

- TB may come back
- serious infection that needs antibiotic
- low blood counts
- development of autoantibodies
- cancers like lymphoma
- severe infusion reaction (allergic reaction)



©2013, Cincinnati Children's Hospital Medical Center. All Rights Reserved.

This work is taken from or based upon information and data from sites contributing to the Pediatric Rheumatology - Care and Outcomes Improvement Network (PR-COIN) www.pr-coin.org and may not be used for commercial purposes.

These medicines do not work right away.

In general, these medicines begin to work between 2 and 12 weeks.

There are ways to manage symptoms until these medicines start working.

Pick another topic



Leflunomide
(Arava®)

**4-8
weeks**

Sulfasalazine
(Azulfidine®)

**4-12
weeks**



Methotrexate
(Rheumatrex® or Trexall®)

**4-6
weeks**



Etanercept
(Enbrel®)

**2-4
weeks**

Adalimumab
(Humira®)

**2-4
weeks**

Anakinra
(Kineret®)

**1-3
weeks**

Canakinumab
(Ilaris®)

**1-3
weeks**



Abatacept
(Orencia®)

**2-12
weeks**

Infliximab
(Remicade®)

**2-4
weeks**

Rituximab
(Rituxan®)

**2-4
weeks**

Tocilizumab
(Actemra®)

**2-4
weeks**

What you pay will depend on your insurance.

Patient assistance programs may be available.



Leflunomide
(Arava®)

Sulfasalazine
(Azulfidine®)

_____ \$ _____



Methotrexate
(Rheumatrex® or Trexall®)



— \$ —



Etanercept
(Enbrel®)

Adalimumab
(Humira®)

Anakinra
(Kineret®)

Canakinumab
(Ilaris®)

_____ \$\$ _____



Abatacept
(Orencia®)

Infliximab
(Remicade®)

Rituximab
(Rituxan®)

Tocilizumab
(Actemra®)

_____ \$\$\$ _____

Pick another topic




©2013, Cincinnati Children's Hospital Medical Center. All Rights Reserved.

This work is taken from or based upon information and data from sites contributing to the Pediatric Rheumatology - Care and Outcomes Improvement Network (PR-COIN) www.pr-coin.org and may not be used for commercial purposes.

Stopping or decreasing the medicine may be considered after the disease is well controlled.

Pick another topic



- How long has the disease been under control?
- Are there bothersome side effects?
- How often does arthritis remain well controlled after stopping?
- What are the treatment options if the arthritis comes back or flares?



©2015, Cincinnati Children's Hospital Medical Center. All Rights Reserved.

This work is taken from or based upon information and data from sites contributing to the Pediatric Rheumatology - Care and Outcomes Improvement Network (PR-COIN) www.pr-coin.org and may not be used for commercial purposes.